Abbott announced the completion of its $23 billion acquisition of Exact Sciences after securing regulatory clearances and shareholder approval. The move brings Cologuard, Oncotype DX and multi‑cancer testing assets into Abbott’s diagnostics portfolio and is expected to add roughly $3 billion of incremental sales in 2026. Abbott said the transaction strengthens its leadership in diagnostics and cancer screening. Commercial context: the acquisition accelerates Abbott’s entry into higher‑growth cancer diagnostics and screening markets and reflects continued consolidation as medical device and diagnostics companies seek scale in precision screening and laboratory services.